Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9612293 | 1.00 | TSHR (0.44) | TSHRHCAR2KEAP1NFE2L2OR51E2 | |
| SCHEMBL4954046 | 1.00 | TSHR (0.44) | TSHRHCAR2KEAP1NFE2L2OR51E2 | |
| SCHEMBL18820281 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL8190669 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL8190673 | 0.94 | TSHR (0.42) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL9535027 | 0.93 | TSHR (0.41) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL9535032 | 0.93 | TSHR (0.41) | TSHRHCAR2KEAP1NFE2L2 | |
| SCHEMBL11722397 | 0.80 | MAPK1 (0.44) | TSHRHCAR2KDM4E | |
| SCHEMBL11725317 | 0.80 | HCAR2 (0.36) | TSHRHCAR2 | |
| SCHEMBL15598874 | 0.80 | MAPK1 (0.44) | TSHRHCAR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022170198-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2017072796-A1 | 2-PYRIDONE BASED COMPOUNDS USEFUL AS POTENTIAL PHOSPHODIESTERASE3A (PDE3A)INHIBITORS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-05-04 | — | — | WO | disclosed |
| US-7361663-B2 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1263726-B1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. | 2003-05-15 | — | — | US | disclosed |
| EP-1263726-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001034567-A1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-17 | — | — | WO | disclosed |
| US-5525731-A | CYCLIZATION; HALOGENATION; ALKYLATION; REDUCTION; HYDROLYSIS; DECARBOXYLATION; SELENYLATION | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1996-06-11 | — | — | US | disclosed |
| US-5446047-A | Anticancer agents | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-08-29 | — | — | US | disclosed |
| US-5391745-A | Cytotoxic activity towards cancer cells | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-02-21 | — | — | US | disclosed |
| US-4053614-A | 1,2-PENTAMETHYLENE-1,4-DIHYDROPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-10-11 | — | — | US | disclosed |
| US-4024261-A | HYPERTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-05-17 | — | — | US | disclosed |
| US-4004015-A | Bicyclic derivatives of 1,4-dihydropyridine as antihypertensive agents and coronary vessel dilators | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-18 | — | — | US | disclosed |
| US-3951994-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951988-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3948923-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-06 | — | — | US | disclosed |
| US-3935220-A | VASODILATION, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | TSHR 2355/4885HCAR2 2957/4885KEAP1 2801/4885 |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | TSHR 4303/4885HCAR2 4555/4885KEAP1 432/4885 |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | TSHR 2355/4885HCAR2 2957/4885KEAP1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.